Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiologicsMD has entered into a manufacturing contract with Cytovance Biologics to continue development of BiologicMD's osteoporosis medication, PTH-CBD.
Subscribe to our email newsletter
The agreement will focus on developing the manufacturing platform for PTH-CBD, that will allow BiologicsMD to conduct Phase I studies.
BiologicsMD president Paul Mlakar said Cytovance expertise will play a key role in accelerating the development of the compound that will hopefully improve the lives of the millions of individuals who suffer from osteoporosis.
BiologicsMD is developing a new prescription osteoporosis medication called PTH-CBD, which promises five times the efficacy of available bisphosphonate treatments with fewer side effects.
Cytovance Biologics president and chief executive officer Darren Head said, "Our experienced staff and state-of-the-art facilities are prepared to deliver the highest quality of manufacturing services for successful completion of this clinical milestone for the PTH-CBD program."